EOFlow has made the first shipment of the world's second wearable insulin pump, EOPatch, to the European market.

EOPatch is a new-generation wearable insulin pump that succeeded in commercialization, solving the problem of long infusion lines in existing pumps, which had limited free movement for users. EOFlow's product has a compact and lightweight design that allows insulin injections for up to 84 hours or 3.5 days. The product received the Conformite Europeenne mark in May.

In 2019, the company signed a 150 billion won ($127 million) deal with Menarini, one of the world's 50 largest pharmaceutical companies, to export EOPatch to Europe for five years.

Menarini will brand the product as GlucoMen Day PUMP in Europe. It has introduced and began showcasing GlucoMen Day PUMP at a meeting held by the European Association for the Study of Diabetes (EASD) from Tuesday.

EOFlow aims to launch the product in 17 European countries in the first half of next year, beginning with major European countries in the fourth quarter of this year, a company official said. In addition, the company plans to export its insulin pumps to other markets, including China and the Middle East, before expanding business to the global market.

"The recent shipment is a significant event for EOFlow. Since the development of the first domestic wearable insulin pump, we have taken a firm root in the domestic market, and is taking the first step in the European market," EOFlow CEO Kim Jae-jin said. "We plan to accelerate research and development to introduce new products following the insulin pump, and expand market share by strengthening product lineups with high value."